Reduced serum paraoxonase 1 (PON1) activity in patients with schizophrenia treated with olanzapine but not quetiapine

Basit Öğe Kaydı
dc.authorid0000-0002-8892-0439
dc.authorscopusid26432848600
dc.authorscopusid29067508300
dc.authorscopusid55892061800
dc.authorscopusid55891056300
dc.authorscopusid55365316700
dc.authorwosidAlbayrak, Yakup/ABA-7651-2020
dc.authorwosidHashimoto, Kenji/I-5800-2015
dc.contributor.authorÜnsal, Cüneyt
dc.contributor.authorAlbayrak, Yakup
dc.contributor.authorAlbayrak, Neslihan
dc.contributor.authorKuloğlu, Murat
dc.contributor.authorHashimoto, Kenji
dc.date.accessioned2022-05-11T14:41:04Z
dc.date.available2022-05-11T14:41:04Z
dc.date.issued2013
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Ruh Sağlığı ve Hastalıkları Ana Bilim Dalı
dc.description.abstractBackground: Second generation antipsychotics (SGAs) are currently the most prescribed drugs in the treatment of schizophrenia. Despite their advantages, which include greater improvement in negative symptoms, cognitive function, prevention of deterioration, quality of life, and fewer extrapyramidal symptoms, the concern regarding metabolic abnormalities which might cause cardiovascular diseases during treatment with SGAs have been rising. Paraoxonase 1 (PON1) is an enzyme mostly located on high-density lipoprotein particles, and has been shown to protect or inhibit lipoprotein oxidation. Growing evidence suggests that PON1 plays a key role in the pathophysiology of atherosclerosis. Methods: In the present study, we measured serum PON1 activity and serum levels of total cholesterol (TC), triglyceride, high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) in patients with schizophrenia, who had been treated with either olanzapine or quetiapine, and in healthy controls. Thirty five patients who had been treated with olanzapine, 29 patients who had been treated with quetiapine, and 32 age, sex, and smoking status-matched healthy control (HC) participants were enrolled. Serum PON1 activity and serum levels of TC, triglyceride, HDL-C, and LDL-C were measured. Results: Serum PON1 activity in the olanzapine group was significantly lower than that of HC and quetiapine groups. Furthermore, serum levels of TC and LDL-C in the olanzapine group were significantly higher than those of quetiapine and HC groups. Interestingly, there was a positive correlation between PON1 activity and HDL-C levels in the olanzapine group. Conclusion: These findings suggest that serum PON1 activity in patients treated with olanzapine was lower than that of HC and quetiapine groups, and that PON1 may play a role in the metabolic side effects associated with olanzapine treatment. A further study to examine the relationship between serum PON1 activity and cardiovascular and metabolic side effects during treatment with SGAs will be of great interest.
dc.identifier.doi10.2147/NDT.S52463
dc.identifier.endpage1552
dc.identifier.issn1178-2021
dc.identifier.pmid24143103
dc.identifier.scopus2-s2.0-84885904056
dc.identifier.scopusqualityQ2
dc.identifier.startpage1545
dc.identifier.urihttps://doi.org/10.2147/NDT.S52463
dc.identifier.urihttps://hdl.handle.net/20.500.11776/9046
dc.identifier.volume9
dc.identifier.wosWOS:000325452300001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorÜnsal, Cüneyt
dc.institutionauthorAlbayrak, Yakup
dc.language.isoen
dc.publisherDove Medical Press Ltd
dc.relation.ispartofNeuropsychiatric Disease and Treatment
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectsecond generation antipsychotics
dc.subjectSGA
dc.subjectatherosclerosis
dc.subjectmetabolic
dc.subjectdyslipidemia
dc.subjectLDL-C
dc.subjectHeart-Disease Risk
dc.subjectAtypical Antipsychotics
dc.subjectTriglyceride Levels
dc.subjectWeight-Gain
dc.subjectLipid-Levels
dc.subjectGene Pon1
dc.subjectArylesterase
dc.subjectRisperidone
dc.subjectDrugs
dc.subjectHyperlipidemia
dc.titleReduced serum paraoxonase 1 (PON1) activity in patients with schizophrenia treated with olanzapine but not quetiapine
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
9046.pdf
Boyut:
442.73 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Tıp Fakültesi Koleksiyonu